Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed)
The summary for the Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) resulting in durable anti-cancer responses. Studies should be largely pre-clinical involving clinically-relevant models and endpoints.
Federal Grant Title: | Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Environment Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-CA-19-015 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.113, 93.121, 93.273, 93.353, 93.853, 93.855 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | February 8th, 2019 |
Original Application Deadline: | February 8th, 2019 |
Posted Date: | October 31st, 2018 |
Creation Date: | October 31st, 2018 |
Archive Date: | March 16th, 2019 |
Total Program Funding: | $7,000,000 |
Maximum Federal Grant Award: | $500,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | October 31st, 2018 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-015.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Re...
- • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...
- • Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clini...
- • Outstanding New Environmental Scientist Award (ONES)
- • Environmental Health Sciences Core Center Grants
- • Leiomyomata Uteri: Basic Science and Translational Research
- More Grants from the National Institutes of Health
- • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
- • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...